Evogene Ltd. (EVGN) intrinsic value & 10-year financials
Evogene Ltd. (EVGN) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 5.7% a year to $3.9M, with an average return on invested capital of -56.3%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- $3.9M
- Revenue growth (10-yr CAGR)
- -5.7%
- ROIC (10-yr avg)
- -56.3%
- Free cash flow (FY2025)
- -$13.6M
EVGN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $3.9M | -$7.8M | $1.08 | -$13.6M | -364.2% | -104.7% |
| FY2024 | $8.5M | -$18.1M | -$2.89 | -$20.3M | -261.0% | -102.1% |
| FY2023 | $5.6M | -$26.0M | -$0.52 | -$22.4M | -470.0% | -83.4% |
| FY2022 | $1.7M | -$29.8M | -$0.65 | -$24.8M | -1608.4% | -54.9% |
| FY2021 | $930.0K | -$30.4M | -$0.69 | -$25.6M | -3328.3% | -51.5% |
| FY2020 | $1.0M | -$26.2M | -$0.83 | -$20.2M | -2386.0% | -42.4% |
| FY2019 | $753.0K | -$19.1M | — | -$18.6M | -2810.9% | -38.3% |
| FY2018 | $1.7M | -$20.8M | — | -$15.5M | -1144.2% | -33.4% |
| FY2017 | $3.4M | -$20.8M | — | -$16.5M | -649.1% | -28.0% |
| FY2016 | $6.5M | -$19.6M | — | -$12.5M | -322.5% | -24.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Evogene Ltd. is facing top-line stagnation, with revenue contracting over the decade.
Evogene Ltd. 10-year average ROIC is N/A; capital efficiency cannot be assessed from the available history.
Over the decade, Evogene Ltd. shows that management has aggressively returned capital to shareholders by retiring 69.1% of outstanding shares.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Evogene Ltd. is modeled at -5.7% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-2.72 per share.